<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570957</url>
  </required_header>
  <id_info>
    <org_study_id>MT-2990-J01</org_study_id>
    <nct_id>NCT03570957</nct_id>
  </id_info>
  <brief_title>A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients</brief_title>
  <official_title>A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients (Single Dose Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the safety, tolerability, and pharmacokinetics
      of MT-2990 in patients with Japanese cedar pollen-induced seasonal allergic rhinitis
      (JC-SAR). Additional objective of the study is to investigate the efficacy and
      pharmacodynamics profile of MT-2990 in an environmental exposure chamber (EEC) on Day 8, 29,
      57, and 85.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Actual">December 27, 2018</completion_date>
  <primary_completion_date type="Actual">December 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by incidence of adverse events</measure>
    <time_frame>Up to Day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who develop antibodies against MT-2990 in serum</measure>
    <time_frame>Up to Day 113</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MT-2990 concentration in serum</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured time of maximum observed serum concentration (tmax) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to the last measurable concentration (AUC0-last) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to infinity (AUC0-∞) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (kel) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase after IV administration (Vz) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time from time zero to infinity (MRT0-∞) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent serum clearance (CL) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC obtained by extrapolation (%AUCex) of MT-2990</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total nasal symptom score (TNSS)</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
    <description>Four nasal symptoms (runny nose, sneezing, blocked nose, and itchy nose) are recorded using a 5-point scale of 0 (none) to 4 (very severe). TNSS is sum of 4 nasal symptoms, score range is 0 to 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ocular symptom score (TOSS)</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
    <description>Two ocular symptoms (itchy eyes and watery eyes) are recorded using a 5-point scale of 0 (none) to 4 (very severe). TOSS is sum of 2 ocular symptoms, score range is 0 to 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total symptom score (TSS)</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
    <description>TSS is TNSS plus TOSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TNSS</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
    <description>Baseline is pre-exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TOSS</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TSS</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of TNSS during allergen exposure in EEC</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of TOSS during allergen exposure in EEC</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of TSS during allergen exposure in EEC</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of TNSS after allergen exposure</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of TOSS after allergen exposure</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of TSS after allergen exposure</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with increased TNSS from baseline</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with increased TOSS from baseline</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with increased TSS from baseline</measure>
    <time_frame>Day 8, 29, 57, and 85</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>MT-2990, Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-2990, Low-middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-2990, High-middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-2990, High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-2990</intervention_name>
    <description>MT-2990 solution for injection in vial</description>
    <arm_group_label>MT-2990, High dose</arm_group_label>
    <arm_group_label>MT-2990, High-middle dose</arm_group_label>
    <arm_group_label>MT-2990, Low dose</arm_group_label>
    <arm_group_label>MT-2990, Low-middle dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution for injection in vial</description>
    <arm_group_label>MT-2990, High-middle dose</arm_group_label>
    <arm_group_label>MT-2990, Low dose</arm_group_label>
    <arm_group_label>MT-2990, Low-middle dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A body weight of 40 to 100 kg for female or 45 to 100 kg for male

          -  A body mass index of 18 to 30 kg/m2

          -  Subjects who have current history of JC-SAR in previous 2 consecutive years.

          -  Presence (CAP-RAST: ≥2) of IgE specific to Japanese cedar pollens and absence
             (CAP-RAST: ≤1) of IgE specific to other 4 allergens

          -  Presence of at least 2 symptoms, which are moderate to very severe, in 4 nasal
             symptoms (runny nose, sneezing, blocked nose, itchy nose) at any time point during
             allergen exposure in EEC at screening period

        Exclusion Criteria:

          -  Presence of any symptoms of allergic rhinitis within 1 year except scattering season
             of cedar pollen or cypress pollen

          -  Subjects who have persistent symptom caused by allergen exposure in EEC at screening
             period until Day 1 (pre-dose)

          -  Underwent nasal surgery (include laser surgery) to improve nasal symptoms within 2
             years

          -  Underwent specific immunotherapy or non-specific immunotherapy within 5 years

          -  Underwent medication of anti-histamine, oral mast cell stabilizer, leukotriene
             receptor antagonist, prostaglandin D2/thromboxane A2 receptor antagonist, Th2 cytokine
             inhibitor, corticosteroid (oral form, intra-nasal form, ocular form), or
             vasoconstrictor within 4 weeks

          -  Underwent medication of corticosteroid (injection form) or anti-IgE antibody within 6
             months

          -  Subject who is concerned about exacerbation of the physical condition due to allergen
             exposure in EEC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

